UK doubles down on Unitary Patent system


Following the surprise ratification of the Unified Patent Court Agreement by the UK on World IP Day 2018, a new Brexit white paper published last week confirms that the UK intends to explore how it can stay part of the UPC Agreement after the UK leaves the EU on 29 March 2019.

Read full story

A Tale of Two Dasatinibs


Things could be looking up for Bristol-Myers Squibb after a tumultuous year that saw the EPO Board of Appeal confirm the revocation of EP1169038, a patent protecting the successful cancer drug dasatinib (Sprycel®). This decision (T488/16) raised eyebrows in February 2017 when the Board of Appeal ruled that in the complete absence of any activity data, the patentee was unable to shift the burden of proof to show the technical effect was plausible at the time of filing and therefore refused to admit the post-filed data that could have corroborated an inventive step.

Read full story

Why LGBTQAI+ pride is important


The annual Pride in London march will take place tomorrow, 7 July 2018. But what is pride in the LGBT+ context, and why does it matter? Partner Tom Leonard muses on the history of LGBT+ Pride and why it is as important as ever.

Read full story

Actavis v. ICOS – The death knell for dosage regime patents in the UK?


This article looks at the Actavis v. ICOS decision, analysing the importance of “expectation of success” when patenting a novel dosage regime. Could this spell the end of dosage regime patents? Moreover, could this decision have broader implications with other inventive step scenarios where it might be “obvious to try”?

Read full story

Top-tier in the UK for patent professionals


We have another excellent write-up in a leading directory this year, IAM Patent 1000. We are thrilled to once again be ranked top-tier in the UK for patent professionals.

Read full story

European Commission publishes guidance Notice on impact of Brexit on Supplementary Protection Certificates


The European Commission has published the following notice on 24 April 2018 concerning the impact of the UK’s departure from the European Union (“Brexit”) on the system for obtaining Supplementary Protection Certificates (SPCs). The SPC system provides for patent term extension for certain medicines and agrochemical requiring the grant of a marketing authorisation to be placed on the market in Europe.

Read full story

Kilburn & Strode opens in The Hague


We’re pleased to announce that we’ve opened a new office in The Hague, where the European Patent Office (EPO) has its second-largest presence, after Munich. Together with our offices in London and Munich, we believe our new space in The Hague makes us the only leading firm of European patent and trade mark attorneys with a presence in each of these three European centres of IP.

Read full story

Life Sciences and Chemistry team welcomes a new Senior Associate


We are delighted to welcome new Senior Associate Mark Abthorpe to our Life Sciences and Chemistry team. Mark joins us as a lateral hire from another London-based firm of patent and trade mark attorneys.

Read full story

NEWS FLASH – UK Ratified the UPC Agreement today


In a dramatic twist in the fortunes of the UPC, the UK government ratified the Unified Patent Court Agreement at 1630 today. That leaves Germany as the outlier and all eyes will now be trained on the constitutional tussle in the German courts.

Read full story

Giving back to create change: Kilburn & Strode launches Innovation for All Foundation on World IP Day 2018


On World IP Day 2018, Kilburn & Strode launched our Innovation for All Foundation. Charitable in nature, 1% of annual profits now provide support and resource to get most creative ideas and brilliant visions off the ground.

Read full story